EUVIMEDEUVIMED entdecken
LeserbriefKommentar

Primary HPV Screening vs Cotesting for Cervical Cancer

Annika Brakebill, Anna Morgan, Richard W Lieberman

JAMA · 05.12.2023 · 330 (21) · 2121

DOI: 10.1001/jama.2023.20370 ↗

Kurz gefasst

Leserbrief in der Zeitschrift JAMA, erschienen am 05.12.2023. Verfasst von Annika Brakebill und 2 weiteren Autor:innen. Beteiligte Einrichtung: University of Michigan Medical School, Ann Arbor. Hauptthemen laut MEDLINE: Early Detection of Cancer, Mass Screening, Papillomavirus Infections, Uterine Cervical Dysplasia. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Early Detection of CancerMass ScreeningPapillomavirus InfectionsUterine Cervical DysplasiaUterine Cervical NeoplasmsVaginal SmearsFemaleHumansPapillomaviridae

Autor:innen und Institutionen

  • University of Michigan Medical School, Ann Arbor.
  • Departments of Obstetrics & Gynecology and Pathology, University of Michigan, Ann Arbor.

Zitieren

APA

Brakebill, A., Morgan, A., & Lieberman, R. W. (2023). Primary HPV Screening vs Cotesting for Cervical Cancer. JAMA, 330(21), 2121. https://doi.org/10.1001/jama.2023.20370

Vancouver

Brakebill A, Morgan A, Lieberman RW. Primary HPV Screening vs Cotesting for Cervical Cancer. JAMA. 2023;330(21):2121. doi:10.1001/jama.2023.20370

BibTeX
@article{Brakebill2023,
  author = {Brakebill, Annika and Morgan, Anna and Lieberman, Richard W},
  title = {Primary HPV Screening vs Cotesting for Cervical Cancer},
  journal = {JAMA},
  year = {2023},
  volume = {330},
  number = {21},
  pages = {2121},
  doi = {10.1001/jama.2023.20370}
}
Kostenlos starten →